Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

On 'The Adam Carolla Show' podcast, healthcare industry watchdog and wellness expert Calley Means shares why he believes the left used to question pharmaceutical companies, big institutions, and war ...

As Robert F. Kennedy Jr. settles into his role as President Donald Trump’s health secretary, one major promise he’s made is ...

Kneat's SaaS model automates validation processes in pharma and biotech, reducing errors and ensuring compliance. Learn why ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Soliman said consumers could see price increases or shortages of generic drugs in the country. There are some laws that ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, ...

Somehow Washington regards the industry, which has saved and improved tens of millions of lives, as a villain.

Using detailed financial reports from thousands of firms, the researchers found that in 2018, U.S. multinationals shifted about $20-25 billion to tax havens — far lower than prior estimates of about ...